POS1062 THERAPEUTIC POTENTIAL OF IMVOTAMAB, A CD20-TARGETED BISPECIFIC IGM T CELL ENGAGER, FOR THE TREATMENT OF REFRACTORY AUTOIMMUNE DISEASE PATIENTSRacquel Domingo-Gonzalez, M. Harler, Maya K. Leabman et al.|Annals of the Rheumatic Diseases|2024Cited by 9
Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s LymphomaKathryn Logronio, M. F. Kotturi, Mugdha V. Joglekar et al.|Hematological Oncology|2023Cited by 2
Abstract 4120: Depletion of tissue-resident B cells by a CD20xCD3 IgM bispecific T cell engager in cynomolgus monkeys demonstrates effective tissue penetration and potent target cell killingMiho Oyasu, Maya F. Kotturi, Bruce A. Keyt et al.|Cancer Research|2023Cited by 0